FAP and neoplasm: After the successful establishment of a more resistant version of our syngeneic tumor model allowing the evaluation of the antitumor efficacy of combinatorial therapeutic strategies, we treated mice showing tumors of approximately 100 mm3 volume with DB in combination with the immunocytokine FAP-IL-2v (Figure 7B).